Considering Race and Ancestry in Precision Approaches to Cancer Care
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this presentation, Dr. John D. Carpten discusses his work in studying the genomics of cancer types that disproportionately impact underrepresented minorities. He focuses on the geographic and racial ancestry of these vulnerable populations, how they affect cancer risk, and how they can be utilized in precision medical treatment.
This Precision Medicine Grand Rounds session will take place on Thursday, March 30, 2023 at 12:00 p.m. and has been approved for Ethics credit.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
Most medical professionals have insufficient knowledge about the role that precision medicine has in clinical practice. Genetic alterations affect all types of cancer and often affect cardiovascular, autoimmune, and neurological diseases. Laboratory tools used in precision medicine are highly sophisticated and include genomics, proteomics, and other high-dimensional assays. The series will provide regular updates on these tools, the ways the tools could improve patient care, and the ethical and legal issues surrounding genetic testing. The series will also examine how testing for genetically influenced diseases can affect personalized management of individuals and their families.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Demonstrate greater understanding of cancer disparities and how they are related to population groups often defined by health disparities.
- Identify racial groups most often affected by cancer disparities.
- Distinguish race from genetic ancestry.
- Recognize how not considering race and/or ancestry affects precision medicine approaches to cancer diagnosis and treatment.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Nurses
- Other Health Professionals
Specialties
- Medical Genetics and Genomics
Interest Groups
- Ethics
- Hospital Medicine
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designated by Baylor College of Medicine for 1 credit of education in medical ethics and/or professional responsibility.
Activity Director
-
Christopher Amos, Ph.D.
Director for the Institute of Clinical and Translational Medicine
Baylor College of Medicine
Term of Approval
March 1, 2023 through March 31, 2025. Original release date: March 1, 2023.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
John D. Carpten, Ph.D.
Royce and Mary Trotter Chair in Cancer Research; Professor and Chair, Department of Translational Genomics
Keck School of Medicine of University of Southern California
Disclosure:
- Advisory Committee Membership: Astra Zeneca; Bristol Meyers Squibb; Roche/Genetech
Activity Director
-
Christopher Amos, Ph.D.
Director for the Institute of Clinical and Translational Medicine
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Christopher Amos, Ph.D.
Director for the Institute of Clinical and Translational Medicine
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
Richard A. Gibbs, Ph.D.
Wofford Cain Chair and Professor, Director of the Baylor College of Medicine Human Genome Sequencing Center
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Bo Peng, Ph.D.
Associate Professor of Medicine, Epidemiology and Population Science
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Rowland Pettit, Ph.D.
Medical Scientist Training Program (MD/PhD)
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: